Germ Cell Tumors of the Gonads: A Selective Review Emphasizing Problems in Drug Resistance and Current Therapy Options
暂无分享,去创建一个
P. Albers | C. Stephan | K. Jung | K. Miller | M. Lein | M. Schrader | M. Schostak | H. Krause | C. Kempkensteffen | S. Hinz | F. Christoph | S. Weikert | M. Hoepfner
[1] K. Miller,et al. The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours. , 2007, International journal of andrology.
[2] J. Baselga,et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] W. Siegert,et al. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. , 2006, European journal of cancer.
[4] M Mazumdar,et al. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Bray,et al. Trends in testicular cancer incidence and mortality in 22 European countries: Continuing increases in incidence and declines in mortality , 2006, International journal of cancer.
[6] J. Masters,et al. Regulation of DNA repair gene expression in human cancer cell lines , 2006, Journal of cellular biochemistry.
[7] W. Voigt,et al. Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] S. Groshen,et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. , 2006, Pharmacogenomics.
[9] M. Spinella,et al. A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma , 2005, Oncogene.
[10] G. Rustin,et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial , 2005, The Lancet.
[11] H. Schmoll,et al. Feasibility of a combination of high dose chemotherapy ifosfamide, carboplatin, etoposide (ICE) plus stem cells and bevacizumab in refractory sarcoma and germ cell tumors , 2005 .
[12] G. Bepler,et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. , 2005, Chest.
[13] J. Fleshman,et al. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer , 2005, British Journal of Cancer.
[14] C. Dumontet,et al. Chemoresistance in non-small cell lung cancer. , 2005, Current medicinal chemistry. Anti-cancer agents.
[15] W. Siegert,et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] C. Bokemeyer,et al. Xeroderma Pigmentosum Group A Protein and Chemotherapy Resistance in Human Germ Cell Tumors , 2003, Laboratory Investigation.
[17] J. Masters,et al. Curing metastatic cancer: lessons from testicular germ-cell tumours , 2003, Nature Reviews Cancer.
[18] J. Richie. Role of P53 and MDM2 in treatment response of human germ cell tumors. , 2003, The Journal of urology.
[19] S. Groshen,et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. , 2003, Clinical advances in hematology & oncology : H&O.
[20] C. Bokemeyer,et al. Molecular determinants of treatment response in human germ cell tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] A. Grothey,et al. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. , 2003, Cancer research.
[22] I. Herskowitz,et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] S. Lippard,et al. Testis-specific HMG-domain protein alters the responses of cells to cisplatin. , 2002, Journal of inorganic biochemistry.
[24] J. Cairns. Somatic stem cells and the kinetics of mutagenesis and carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] L. Looijenga,et al. Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. , 2002, Cancer research.
[26] S. Lutzker,et al. A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells , 2001, Oncogene.
[27] K. Karplus,et al. Nucleotide excision repair "a legacy of creativity". , 2001, Mutation research.
[28] S. Chew,et al. An exonic splicing silencer in the testes-specific DNA ligase III β exon , 2000 .
[29] S. Chew,et al. An exonic splicing silencer in the testes-specific DNA ligase III beta exon. , 2000, Nucleic acids research.
[30] Paulus We. Pharmacotherapy in pregnancy , 1999 .
[31] M. Benahmed,et al. Stem cell factor/c-kit system in spermatogenesis. , 1999, Human reproduction update.
[32] R. Wood,et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours , 1999, Current Biology.
[33] C. Chresta,et al. Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis , 1999, Oncogene.
[34] W. Paulus. [Pharmacotherapy in pregnancy]. , 1999, Therapeutische Umschau. Revue therapeutique.
[35] D. D. de Rooij,et al. The effect of 9-cis-retinoic acid on proliferation and differentiation of a spermatogonia and retinoid receptor gene expression in the vitamin A-deficient mouse testis. , 1998, Endocrinology.
[36] D. D. de Rooij,et al. Differential expression pattern of retinoid X receptors in adult murine testicular cells implies varying roles for these receptors in spermatogenesis. , 1998, Biology of reproduction.
[37] D. D. de Rooij,et al. Isolation and characterization of all‐trans‐retinoic acid–responsive genes in the rat testis , 1998, Molecular reproduction and development.
[38] H. Gerhartz,et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. , 1998, Seminars in oncology.
[39] P. Catalano,et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] R. Braun. Every sperm is sacred—or is it? , 1998, Nature Genetics.
[41] R Sylvester,et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Lippard,et al. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. , 1998, Biochemistry.
[43] S. Lippard,et al. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. , 1997, Biochemistry.
[44] V. Torri,et al. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. , 1997, Gynecologic oncology.
[45] H. Kampinga,et al. Heat‐shock protein expression in cisplatin‐sensitive and ‐resistant human tumor cells , 1996, International journal of cancer.
[46] A. Levine,et al. A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation , 1996, Nature Medicine.
[47] A. Hall,et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. , 1996, European journal of cancer.
[48] L. Weber,et al. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. , 1996, Cancer research.
[49] C. Chresta,et al. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. , 1996, Cancer research.
[50] J. Hickman,et al. Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. , 1995, British Journal of Cancer.
[51] L. Panasci,et al. DNA repair enzyme expression in chronic lymphocytic leukemia vis-à-vis nitrogen mustard drug resistance. , 1995, Cancer letters.
[52] N. Mulder,et al. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. , 1995, British Journal of Cancer.
[53] M. Dym. Spermatogonial stem cells of the testis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[54] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[55] D. Lamb,et al. Growth factors and testicular development. , 1993, The Journal of urology.
[56] Scott W. Lowe,et al. p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.
[57] S. Nishikawa,et al. Role of c-kit in mouse spermatogenesis: identification of spermatogonia as a specific site of c-kit expression and function. , 1991, Development.
[58] L. Einhorn,et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] J. Masters,et al. Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies. , 1990, Cancer research.
[60] M. Green,et al. Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines. , 1988, International journal of radiation biology and related studies in physics, chemistry, and medicine.
[61] F. Friedlos,et al. Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. , 1987, Cancer research.
[62] P. Andrews,et al. Effects of CIS‐platinum on embryonal carcinoma cell lines in vitro , 1984, International journal of cancer.
[63] Rainer Frentzel-Beyme,et al. Krebsatlas der Bundesrepublik Deutschland / Atlas of Cancer Mortality in the Federal Republic of Germany 1981–1990 , 1984 .
[64] L. Einhorn,et al. Improved chemotherapy in disseminated testicular cancer. , 1977, The Journal of urology.
[65] C. Huckins. The spermatogonial stem cell population in adult rats. I. Their morphology, proliferation and maturation , 1971, The Anatomical record.